Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Pepper, Dominique J ^a,b   Marais, Suzaan ^a,b   Wilkinson, Robert J ^a,b,c,d   Bhaijee, Feriyl ^e   Maartens, Gary ^b   McIlleron, Helen ^b   De Azevedo, Virginia ^f   Cox, Helen ^g   McDermid, Cheryl ^h   Sokhela, Simiso ^f   Patel, Janisha ^b   Meintjes, Graeme ^a,b  

^a GF Jooste Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f Khayelitsha Site B   (South Africa)

^g MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^h Medecins Sans Frontieres   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; CAUSAL ATTRIBUTION; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DETERIORATION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; RISK FACTOR; TREATMENT DURATION; TUBERCULOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT FAILURE; VIROLOGY;

AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TUBERCULOSIS;

EID: 77950390077     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-83     Document Type: Article

References (26)

1. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991, 324(5):289-94.
2. Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr 2002, 29(5):429-34.
3. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M, . Antiretroviral Therapy (ART) Cohort Collaboration HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006, 368(9534):451-8. 10.1016/S0140-6736(06)69152-6, 16890831, Antiretroviral Therapy (ART) Cohort Collaboration.
4. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deterioration during antituberculosis treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One 2009, 4(2):e4520. 10.1371/journal.pone.0004520, 2642598, 19229341.
5. Zachariah R, Fitzgerald M, Massaquoi M, Acabu A, Chilomo D, Salaniponi FM, Harries AD. Does antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi?. Int J Tuberc Lung Dis 2007, 11(8):848-53.
6. Karim SA, Naidoo K, Grobler A, Padayatchi N, Nair G, Bamber S, Pienaar J, Friedland G, El-Sadr W, Karim QA. Initiating ART during TB Treatment Significantly Increases Survival: Results of a Randomized Controlled Clinical Trial in TB/HIV-co-infected Patients in South Africa. CROI 2009 Abstract #36a Session 8 Oral Abstracts Prevention and Treatment of Serious OIs and Malignancies , http://www.retroconference.org/2009/Abstracts/34255.htm
7. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R, . International Network for the Study of HIV-associated IRIS Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8(8):516-23. 10.1016/S1473-3099(08)70184-1, 2804035, 18652998, International Network for the Study of HIV-associated IRIS.
8. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ. Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discov Today 2007, 12:980-9. 10.1016/j.drudis.2007.08.001, 17993418.
9. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006, 50:1170-7. 10.1128/AAC.50.4.1170-1177.2006, 1426981, 16569826.
10. Karim SS, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009, 374(9693):921-33. 10.1016/S0140-6736(09)60916-8, 2803032, 19709731.
11. Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis 1998, 2(11):919-25.
12. Zwang J, Garenne M, Kahn K, Collinson M, Tollman SM. Trends in mortality from pulmonary tuberculosis and HIV/AIDS co-infection in rural South Africa (Agincourt). Trans R Soc Trop Med Hyg 2007, 101(9):893-8. 10.1016/j.trstmh.2007.04.023, 17597174.
13. Results of the 2006 HIV-1 Antenatal Provincial and Area Surveys. 2007, Cape Town: Western Cape Provincial Department of Health.
14. South African National Tuberculosis Control Programme Practical guidelines. [Accessed 7 September 2009].., http://www.doh.gov.za/aids/docs/tuberculosis.html
15. South African Department of Health HIV-1 and AIDS and STI strategic plan for South Africa 2007-2011. [Accessed 7 September 2009].., http://www.info.gov.za/otherdocs/2007/aidsplan2007/index.html
16. World Health Organization Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents recommendations for HIV-1-prevalent and resource-constrained settings. [Accessed 7 September 2009]., World Health Organization., http://www.who.int/tb/publications/2006/tbhiv_recommendations.pdf
17. Hain Lifescience GenoType MTBDRplus, version 1.0. [Accessed 24 September 2009]., Hain Lifescience., http://www.hain-lifescience.de/en/products/microbiology/mycobacteria/genotype-mtbdrplus.html
18. WHO HIV Clinical Staging. [Accessed 24 September 2009]., WHO., http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf
19. El Sadr, et al. CD4+ Count-Guided Interruption of Antiretroviral Treatment: The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N Engl J Med 2006, 355:2283-96. 10.1056/NEJMoa062360, 17135583.
20. Sterling TR, Zhao Z, Khan A, Chaisson RE, Schluger N, Mangura B, Weiner M, Vernon A. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 2006, 10(5):542-549.
21. Corbett EL, Churchyard GJ, Charalambos S, Sam B, Maloi B, Clayton T, Grant AD, Murray J, Hayes RJ, De Cock KM. Morbidity and Mortality in South African Gold Miners: Impact of Untreated Disease Due to Human Immunodeficency Virus. Clinical Infectious Diseases 2002, 34:1251-8. 10.1086/339540, 11941552.
22. Martinson NA, Karstaedt A, Venter F, Omar T, King P, Mbengo T, Marais E, McIntyre J, Chaisson RE, Hale M. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007, 21:2043-2050. 10.1097/QAD.0b013e3282eea47f, 17885294.
23. Dirienzo AG, Horst C, Finkelstein DM, FRAME P, Bozzette SA, Tashima KT. Efficacy of Trimethoprim-Sulfamethoxazole for the Prevention of Bacterial Infections in a Randomized Prophylaxis Trial of Patients with Advanced HIV Infection. AIDS Research and Human retroviruses 2002, 18(2):89-94. 10.1089/08892220252779629, 11839141.
24. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology 2008, 23:192-202. 10.1111/j.1440-1746.2007.05207.x, 17995946.
25. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002, 16:75-83. 10.1097/00002030-200201040-00010, 11741165.
26. Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ, Wilkinson KA, Wilkinson RJ. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antituberculosis drug resistance. Clin Infect Dis 2009, 48(5):667-76. 10.1086/596764, 2737129, 19191655.